Your browser is no longer supported. Please, upgrade your browser.
CLVS Clovis Oncology, Inc. daily Stock Chart
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-8.23 Insider Own0.40% Shs Outstand48.67M Perf Week-5.36%
Market Cap4.22B Forward P/E- EPS next Y-2.01 Insider Trans-7.15% Shs Float46.61M Perf Month-8.11%
Income-324.20M PEG- EPS next Q-2.09 Inst Own97.90% Short Float16.02% Perf Quarter59.29%
Sales7.10M P/S593.91 EPS this Y7.40% Inst Trans0.39% Short Ratio3.93 Perf Half Y48.64%
Book/sh3.96 P/B21.88 EPS next Y64.50% ROA-73.40% Target Price92.73 Perf Year495.87%
Cash/sh8.40 P/C10.31 EPS next 5Y31.90% ROE-380.90% 52W Range13.43 - 96.92 Perf YTD95.05%
Dividend- P/FCF- EPS past 5Y-29.60% ROI- 52W High-10.61% Beta1.59
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin82.70% 52W Low545.12% ATR4.53
Employees278 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)53.35 Volatility4.63% 4.07%
OptionableYes Debt/Eq1.62 EPS Q/Q38.90% Profit Margin- Rel Volume0.60 Prev Close85.27
ShortableYes LT Debt/Eq1.62 EarningsAug 07 AMC Payout- Avg Volume1.90M Price86.64
Recom2.00 SMA20-5.93% SMA5020.43% SMA20057.63% Volume1,136,856 Change1.61%
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Jun-19-17Upgrade Chardan Capital Markets Sell → Neutral $36 → $50
Jun-16-17Resumed Credit Suisse Outperform
Jun-13-17Initiated Leerink Partners Outperform $85
May-17-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Downgrade Chardan Capital Markets Neutral → Sell $36
Jan-27-17Initiated BofA/Merrill Buy $74
Jan-26-17Upgrade Piper Jaffray Neutral → Overweight
Jan-23-17Reiterated Stifel Buy $52 → $86
Jan-13-17Initiated Morgan Stanley Overweight
Dec-21-16Reiterated WallachBeth Hold $22 → $49
Dec-20-16Upgrade Chardan Capital Markets Sell → Neutral $15 → $36
Oct-25-16Initiated Chardan Capital Markets Sell $15
Sep-23-16Reiterated SunTrust Buy $38 → $50
Sep-21-16Upgrade Credit Suisse Neutral → Outperform
Sep-21-16Reiterated Stifel Buy $30 → $45
Aug-24-16Reiterated Mizuho Neutral $15 → $23
Aug-05-16Initiated SunTrust Buy
Jul-18-17 09:05AM  3 Stocks at 52-Week Highs Still Worth Buying Motley Fool
Jul-13-17 05:37PM  Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion Zacks
Jul-07-17 07:43AM  Here's Why Clovis Oncology Inc. Jumped 70% in June Motley Fool
Jun-30-17 04:14PM  This Rebounding Pharma Stock May Launch Another Breakout Move Investor's Business Daily
Jun-29-17 10:41AM  3 Stocks That Turned $8,000 Into at Least $25,600 in Just One Year Motley Fool
Jun-27-17 03:43PM  Is It Too Late to Buy Clovis Oncology Stock? Motley Fool
07:02AM  Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race? Motley Fool
Jun-26-17 02:52PM  Seattle Genetics: A Disappointing StudyOr Was It?
Jun-23-17 03:40PM  3 Growth Stocks for Bright Investors Motley Fool
09:00AM  Healthcare ETF (IYH) Hits New 52-Week High Zacks
Jun-22-17 01:05PM  Clovis Oncology commencing $250 million stock offering American City Business Journals
11:17AM  5 Reasons Why Biotech ETFs are Soaring Zacks
08:43AM  Clovis Oncology, Inc. (CLVS) Worth a Look: Stock Jumps 6.3% Zacks
Jun-21-17 06:56PM  Clovis Oncology Announces Exercise in Full of Underwriters Option to Purchase Additional Shares of Common Stock Business Wire +6.33%
12:42PM  4 Stocks & ETFs to Buy on Clovis' Positive Drug Data Zacks
09:35AM  Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More Zacks
Jun-20-17 07:06PM  Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock Business Wire
04:43PM  These Biotechs Are Leading The Sector To A 3-Month High Today Investor's Business Daily
04:15PM  Could Tesaro Overcome Clovis' Lead On Combos With Merck & Co.? Investor's Business Daily
02:39PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
12:21PM  Biotech ETFs: Still Riding High
11:10AM  Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study Zacks
09:33AM  Biotech Movers: AveXis, Clovis, Epizyme
08:00AM  Today's Research Reports on Stocks to Watch: Clovis Oncology and Valeant Pharmaceuticals Accesswire
06:00AM  Why These Biotech Stocks Are Gaining Investopedia
12:37AM  [$$] The Dark Side of Good News in Biotech The Wall Street Journal
Jun-19-17 05:28PM  Here's what's behind the biotech breakout CNBC Videos +46.54%
04:55PM  Why This Cancer Drug Specialist Is Up 50% Today Investor's Business Daily
04:38PM  Biotech Flew Nearly 50% On Strong Trial But Is Its Drug Better? Investor's Business Daily
04:15PM  As Clovis Oncology Soars, This Big Pharma Stock Clears New Buy Zone Investor's Business Daily
04:12PM  Clovis Oncology to launch $250 mln stock offering MarketWatch
04:01PM  Clovis Oncology Announces Proposed Offering of Common Stock Business Wire
03:02PM  US STOCKS-Wall St at record highs on technology, health stocks strength Reuters
02:28PM  Biotech stocks are having their best day since February CNBC
02:21PM  Clovis Oncology's Rubraca Notches Key Trial Win Motley Fool
12:37PM  Tesaro: Is The Selloff Overdone?
11:48AM  Why Cancer Biotech Clovis Oncologys Stock Is Soaring Fortune
11:48AM  Here's Why Clovis Oncology (CLVS) Stock Skyrocketed Today Zacks
11:45AM  Why Tesaro Inc. Stock Briefly Dipped Today Motley Fool
11:44AM  [$$] The Dark Side of Good News in Biotech The Wall Street Journal
11:00AM  Why Clovis Oncology Stock Is Soaring Today Motley Fool
10:56AM  Analysts Weigh in on Two Skyrocketing Stocks: Novadaq Technologies Inc. (NVDQ), Clovis Oncology Inc (CLVS) SmarterAnalyst
10:37AM  Clovis surges on positive cancer-drug data CNBC Videos
10:36AM  Clovis's ovarian cancer drug set for label expansion, shares soar Reuters
10:36AM  What's Next For Clovis Oncology?
09:33AM  Story Stocks from
09:08AM  Biotech Movers: Clovis, Seattle Genetics, Rigel
09:00AM  Clovis Oncology Surges on Clutch Late-Stage Ovarian Cancer Trial 24/7 Wall St.
08:51AM  Clovis Oncology stock surges 50% on positive late-stage cancer trial results MarketWatch
03:56AM  Clovis Oncology's cancer drug Rubraca succeeds in key study Reuters
03:45AM  Clovis Oncologys Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial Business Wire
Jun-18-17 07:01PM  New test may turn AZ's Lynparza into precision drug for prostate cancer Reuters
Jun-16-17 04:41PM  Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs? Investor's Business Daily
09:55AM  Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year Zacks
Jun-15-17 01:32PM  ETFs with exposure to Clovis Oncology, Inc. : June 15, 2017 Capital Cube -5.70%
08:36AM  Surging Earnings Estimates Signal Good News for Clovis Oncology, Inc. (CLVS) Zacks
Jun-14-17 09:05AM  Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors GlobeNewswire
Jun-13-17 09:28AM  Biotech Movers: Acceleron, Clovis, Coherus
Jun-12-17 09:40AM  3 Stocks Warren Buffett Can't Buy, but You Can Motley Fool
Jun-06-17 11:54AM  Clovis Oncology, Inc. Value Analysis (NASDAQ:CLVS) : June 6, 2017 Capital Cube
Jun-05-17 08:42AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : June 5, 2017 Capital Cube
Jun-02-17 08:50AM  Implied Volatility Surging for Clovis (CLVS) Stock Options Zacks
Jun-01-17 04:07PM  How Clovis, AstraZeneca Could 'Muddy' A Potential Deal For Tesaro Investor's Business Daily +6.87%
May-23-17 08:00AM  Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting Business Wire
May-22-17 08:58AM  Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain Zacks
May-17-17 05:05PM  Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug? Investor's Business Daily
May-12-17 05:21PM  Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-07-17 08:20PM  Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 04:48PM  How Clovis Might Still Quash AstraZeneca, Tesaro In Cancer Investor's Business Daily
01:29PM  Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update
10:27AM  Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start Zacks
May-03-17 05:44PM  Clovis reports 1Q loss Associated Press
04:05PM  Clovis Oncology Announces First Quarter 2017 Operating Results Business Wire
Apr-27-17 07:05AM  Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment GlobeNewswire
Apr-25-17 03:43PM  Tesaro Inc Bulls Need a Reality Check Motley Fool
Apr-21-17 07:21AM  Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing Motley Fool
06:52AM  Tesaros Zejula Flops as H&S Pattern Emerges Investopedia
Apr-20-17 04:22PM  Tesaro Dives On 'Sticker Shock' For $177,000 Drug Investor's Business Daily
01:21PM  AbbVie's PARP Inhibitor Comes Up Empty Motley Fool
08:00AM  Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3 Business Wire
Apr-17-17 08:42AM  3 Cancer Drug Stocks That Could Make You Rich Motley Fool
Apr-10-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology Accesswire
Apr-07-17 04:53PM  Why Clovis Oncology's Stock Edged Higher in March Motley Fool
Mar-31-17 08:33AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017 Capital Cube
08:33AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017
Mar-29-17 11:41AM  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA Zacks
11:41AM  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA at Investopedia
12:10AM  [$$] Overheard The Wall Street Journal
12:10AM  [$$] Overheard at The Wall Street Journal
Mar-28-17 06:03PM  Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula Investopedia
06:03PM  Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula at Investopedia
04:30PM  Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017 Business Wire
04:19PM  Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer Investor's Business Daily
04:19PM  Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer
09:23AM  Biotech M&A Trade Hits a Snag The Wall Street Journal
09:23AM  Biotech M&A Trade Hits a Snag at The Wall Street Journal
03:30AM  Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report? Zacks
Mar-27-17 08:42PM  Tesaro wins FDA approval for potential blockbuster cancer drug at
04:33PM  Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely Investor's Business Daily
04:33PM  Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its product primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IVERS-READ GILLIAN CSee RemarksJul 17Sale91.563,000274,680197,583Jul 17 06:07 PM
IVERS-READ GILLIAN CSee RemarksJun 15Sale61.823,000185,460200,583Jun 15 05:42 PM
IVERS-READ GILLIAN CSee RemarksMay 15Sale47.393,000142,170203,583May 15 06:24 PM
IVERS-READ GILLIAN CSee RemarksApr 17Sale56.023,000168,060206,583Apr 17 06:04 PM
IVERS-READ GILLIAN CSee RemarksMar 15Sale66.993,000200,970209,583Mar 15 05:15 PM